title: Natural protection against HIV-1 infection provided by HIV-2.
abstract: Significant differences have been observed in the rates of transmission and disease development in human immunodeficiency virus (HIV) types 1 and 2. Because many HIV-2-infected people remain asymptomatic for prolonged periods, the hypothesis that HIV-2 might protect against subsequent infection by HIV-1 was considered. During a 9-year period in Dakar, Senegal, the seroincidence of both HIV types was measured in a cohort of commercial sex workers. Despite a higher incidence of other sexually transmitted diseases (STDs), HIV-2-infected women had a lower incidence of HIV-1 than did HIV-seronegative women, with a relative risk of 0.32 (P = 0.008). An understanding of the cross-protective mechanisms involved may be directly relevant to HIV-1 vaccine development.
authors.affiliation: Department of Cancer Biology, Harvard School of Public Health, Boston, MA 02115, USA.
authors.forename: K
authors.initials: K
authors.lastname: Travers
authors.forename: S
authors.initials: S
authors.lastname: Mboup
authors.forename: R
authors.initials: R
authors.lastname: Marlink
authors.forename: A
authors.initials: A
authors.lastname: Guèye-Nidaye
authors.forename: T
authors.initials: T
authors.lastname: Siby
authors.forename: I
authors.initials: I
authors.lastname: Thior
authors.forename: I
authors.initials: I
authors.lastname: Traore
authors.forename: A
authors.initials: A
authors.lastname: Dieng-Sarr
authors.forename: J L
authors.initials: JL
authors.lastname: Sankalé
authors.forename: C
authors.initials: C
authors.lastname: Mullins
mesh_terms: D016915:AIDS Vaccines; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D015986:Confounding Factors, Epidemiologic; D003429:Cross Reactions; D000939:Epitopes / Q000276:immunology; D005260:Female; D015488:HIV Antigens / Q000276:immunology; D015658:HIV Infections / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D006679:HIV Seropositivity; D015497:HIV-1 / Q000276:immunology* / Q000472:pathogenicity; D015498:HIV-2 / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D007113:Immunity, Innate; D015999:Multivariate Analysis; D011446:Prospective Studies; D012044:Regression Analysis; D012675:Senegal; D011477:Sex Work; D014774:Virulence
chemical_list: D016915:AIDS Vaccines; D000939:Epitopes; D015488:HIV Antigens